Keros Therapeutics Inc (OQ:KROS)

Nov 17, 2020 04:01 pm ET
Keros Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders...
Nov 16, 2020 08:00 am ET
Keros Therapeutics to Present at the Jefferies Virtual London Healthcare Conference
Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders...
Nov 12, 2020 10:11 pm ET
Keros Therapeutics Announces Pricing of Public Offering of Common Stock
Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders...
Nov 10, 2020 05:12 pm ET
Keros Therapeutics Announces Proposed Public Offering of Common Stock
Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders...
Nov 10, 2020 04:17 pm ET
Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2020 Financial Results
Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and...
Nov 09, 2020 08:00 am ET
Global Health Sciences Fund (Quark Venture LP and GF Securities) Announces Portfolio Company SQZ Biotechnologies’ IPO
Quark Venture LP (Quark) and GF Securities are pleased to announce the successful listing of portfolio company, SQZ Biotechnologies (NYSE: SQZ) (“SQZ”) on the New York Stock Exchange (NYSE) as of October 30, 2020. This announcement marks Global...
Nov 04, 2020 04:01 pm ET
Keros Therapeutics to Present at the Virtual 62nd American Society of Hematology Annual Meeting and Exposition
Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders...
Oct 20, 2020 08:00 am ET
Keros Therapeutics, Inc. Announces Dosing of First Participants in Phase 2 Clinical Trial of KER-050 in Myelodysplastic Syndromes (MDS)
Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and...
Sep 14, 2020 07:01 am ET
Keros Therapeutics to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders...
Sep 11, 2020 04:01 pm ET
Keros Therapeutics Presents Results from Preclinical Studies Investigating KER-012 at the American Society for Bone and Mineral Research 2020 Annual Meeting
Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and...
Aug 13, 2020 07:00 am ET
Keros Therapeutics Reports Recent Business Highlights and Second Quarter 2020 Financial Results
Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders...
Aug 10, 2020 08:00 am ET
Keros Therapeutics to be Featured on The Balancing Act's "Behind the Mystery" Rare Disease Series
Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and...
Aug 04, 2020 08:00 am ET
Keros Therapeutics, Inc. Announces Completion of Dosing of Planned Cohorts in KER-047 Phase 1 Trial and Provides Program Update
Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and...
Jun 26, 2020 07:01 am ET
Keros Therapeutics Set to Join Russell 2000® Index
Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and...
Jun 12, 2020 07:01 am ET
Keros Therapeutics Presents Results from Clinical and Preclinical Studies Investigating KER-050, along with Preclinical Data from its ALK2 Inhibitor Program, at the European Hematology Association 202
Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders...
May 28, 2020 07:01 am ET
Keros Therapeutics To Present At The Jefferies 2020 Virtual Healthcare Conference
Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders...
May 22, 2020 07:00 am ET
Keros Therapeutics Reports Recent Business Highlights and First Quarter 2020 Financial Results
Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders...
May 14, 2020 09:15 am ET
Keros Therapeutics to Present at the Virtual 25th Annual Congress of the European Hematology Association
Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders...
Apr 13, 2020 04:01 pm ET
Keros Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders...
Apr 07, 2020 08:45 pm ET
Keros Therapeutics Announces Pricing of Initial Public Offering of Common Stock
LEXINGTON, MA / ACCESSWIRE / April 7, 2020 / Keros Therapeutics, Inc. ("Keros") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with a high unmet medical need, today announced the pricing of its initial public offering of 6,000,000 shares of common stock at a public offering price of $16.00 per share, for gross proceeds of $96.0 million, before deducting underwriting discounts and commissions and offering expenses pay

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.